# EDGAR Filing Document

**Accession Number:** 0002068010
**File Stem:** 0001213900-25-085149
**Filing Date:** 2025-9
**Character Count:** 9884
**Document Hash:** feab71464deb50795e654d7603bf34d9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-085149.hdr.sgml**: 20250905

**ACCESSION NUMBER**: 0001213900-25-085149

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250905

**DATE AS OF CHANGE**: 20250905

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Alaunos Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001107421
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 841475642
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-79364
- **FILM NUMBER:** 251297530

**BUSINESS ADDRESS:**
- **STREET 1:** 501 E LAS OLAS BLVD
- **STREET 2:** SUITE 300
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301
- **BUSINESS PHONE:** (346) 355-4099

**MAIL ADDRESS:**
- **STREET 1:** 501 E LAS OLAS BLVD
- **STREET 2:** SUITE 300
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZIOPHARM ONCOLOGY INC
- **DATE OF NAME CHANGE:** 20050919

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EASYWEB INC
- **DATE OF NAME CHANGE:** 20010213
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PMGC CAPITAL LLC
- **CENTRAL INDEX KEY:** 0002068010

**ORGANIZATION NAME:**
- **EIN:** 331978501
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 120 NEWPORT CENTER DRIVE
- **STREET 2:** STE. 250
- **CITY:** NEWPORT BEACH
- **STATE:** CA
- **ZIP:** 92660
- **BUSINESS PHONE:** 888-445-4886

**MAIL ADDRESS:**
- **STREET 1:** 120 NEWPORT CENTER DRIVE
- **STREET 2:** STE. 250
- **CITY:** NEWPORT BEACH
- **STATE:** CA
- **ZIP:** 92660

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Alaunos Therapeutics, Inc.**

*(Name of Issuer)*

**Common Stock**

*(Title of Class of Securities)*

**98973P309**

*(CUSIP Number)*

**Ross D. Carmel, Esq.**<br>Sichenzia Ross Ference Carmel LLP<br>1185 Avenue of the Americas, 31st Floor<br>New York NY 10036<br>2126580458

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**08/22/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **98973P309** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**PMGC CAPITAL LLC** | Name of reporting person<br>**PMGC CAPITAL LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**NEVADA** | Citizenship or place of organization<br>**NEVADA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0%** | Percent of class represented by amount in Row (11)<br>**0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **98973P309** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**PMGC Holdings Inc.** | Name of reporting person<br>**PMGC Holdings Inc.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**NEVADA** | Citizenship or place of organization<br>**NEVADA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0%** | Percent of class represented by amount in Row (11)<br>**0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** PMGC Holdings Inc. ("PMGC Holdings") is, as of the date of this Amendment No. 1, the sole member of PMGC Capital LLC ("PMGC LLC"). As of August 25, 2025 (please refer to Item 4 of this Amendment No. 1, below, for additional detail in relation to this date), the Reporting Persons are no longer beneficial owners or no longer may be deemed to be beneficial owners (as the case may be), of any shares of Common Stock of the Issuer.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock

**(b) Name of Issuer:**
Alaunos Therapeutics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
501 E LAS OLAS BLVD, SUITE 300, FORT LAUDERDALE, FL, 33301

Explanatory Note

Pursuant to Rule 13d-2 promulgated under the Securities Exchange Act of 1934, as amended, this Amendment No. 1 to Schedule 13D (this "Amendment No. 1") amends and supplements the Schedule 13D originally filed with the U.S. Securities and Exchange Commission (the "SEC") on May 14, 2025 (the "Original Schedule 13D").

This Amendment No. 1 ("Amendment No. 1") relates to the common stock, par value $0.001 per share ("Common Stock"), of Alaunos Therapeutics, Inc., a Delaware corporation (the "Issuer"), owned by PMGC Capital LLC and PMGC Holdings Inc. (PMGC Capital LLC and PMGC Holdings Inc., collectively, the "Reporting Persons") and is the final amendment to the Original Schedule 13D and an exit filing for the Reporting Persons.

**Item 4. Purpose of Transaction**

Item 4 is hereby replaced in its entirety as follows:

Between June 16, 2025 and August 22, 2025, PMGC LLC sold all of Common Stock of the Issuer on the open market at prices ranging between $1.92 to $4.53 (such sales, in the aggregate, the "Transactions"). As of August 25, 2025, PMGC LLC's settlement date of the August 22, 2025 sales of the Issuer's Common Stock, the Reporting Persons are no longer beneficial owners or no longer may be deemed to be beneficial owners (as the case may be), of any shares of Common Stock.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5(a) of the Original Schedule 13D is hereby replaced in its entirety as follows:

As of August 25, 2025, the Reporting Persons are no longer beneficial owners or no longer may be deemed to be beneficial owners (as the case may be), of any shares of Common Stock.

**(b)**
Item 5(b) of the Original Schedule 13D is hereby replaced in its entirety as follows:

As of August 25, 2025, the Reporting Persons are no longer beneficial owners or no longer may be deemed to be beneficial owners (as the case may be), of any shares of Common Stock.

**(c)**
Item 5(c) of the Original Schedule 13D is hereby replaced in its entirety as follows:

Between June 16, 2025 and August 22, 2025, PMGC LLC sold all of the Common Stock of the Issuer on the open market at prices ranging between $1.92 to $4.53.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** PMGC CAPITAL LLC

**Signature:** /s/ Graydon Bensler

**Name/Title:** Graydon Bensler, Manager of PMGC Capital LLC

**Date:** 09/05/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** PMGC Holdings Inc.

**Signature:** /s/ Graydon Bensler

**Name/Title:** Graydon Bensler, Chief Executive Officer of PMGC Holdings Inc.

**Date:** 09/05/2025